Abstract:Abstract Abstract 592 Arsenicals represent one group of the oldest drugs used in both traditional Chinese medicine (TCM) and Western medicine since 2,000 years ago to treat a variety of ailments from periodic fever to cancer. Recently, this ancient remedy has been revived due to its remarkable therapeutic efficacy for acute promyelocytic leukemia (APL) through selective degradation of the leukemogenic PML-RARaƒn as well as the wild-type PML protein. However, the precise molecular mechanism leading to arsenic-initiated modulationƒn of the target proteins remained unclear. Here we show that arsenic directly binds to PML and PML-RARaƒn through their RBCC (RING-B box-coiled coil) domain which contains conserved cysteine/histidine residues with metal-binding ability. Among RBCC domain, the RING and B2 motif are responsible for arsenic binding in cells, with recombinant RING motif showing the highest affinity to arsenic binding in vitro. We also observed that arsenic tends to coordinate with three sulfur atoms from the three conserved cysteines in the RING zinc finger. Arsenic binding alters the native structure of RING coordinated with zinc and induces its oligomerization through arsenic-mediated conformational change by intramolecular coordination as well as cross-linking between two RING motifs. Following conformational change and oligomerization of PML RBCC with arsenic binding, PML and PML-RARa undergoes SUMOylation through enhanced interaction with Ubc9, the E2 ligase for SUMOylation. Our findings provide the evidence that the PML RBCC domain is the direct target of arsenic and that the structural change of PML RBCC induced by arsenic binding facilitates the enhanced interaction with the cellular enzymatic machinery for protein SUMOylation/ubiquitination, which ultimately leads to the degradation of PML-RARa and cell differentiation and/or apoptosis. This mechanism sheds new insights into the mechanism of action of As2O3 for APL treatment, a model of targeted cancer therapy. Disclosures: No relevant conflicts of interest to declare.

Supplementary Table S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Supplementary Table S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Supplementary Table S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Supplementary Figure S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Supplementary Figure S5 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Supplementary Movie S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Structural basis of PML/RARA oncoprotein targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function

Data from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Arsenic Binding To Rbcc Domain Modulates Oncogenic Pml-Rara And Wild-Type Pml As A Key Molecular Mechanism Of Arsenic Trioxide Treatment For Apl

Supplementary Materials and Methods, Table 1, Figures 1 - 6 from SCP Phosphatases Suppress Renal Cell Carcinoma by Stabilizing PML and Inhibiting mTOR/HIF Signaling

Identification of a Point Mutation PMLS214L-RARα That Alters PML Body Organization, Dynamics and SUMOylation.

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.